Table 1 Patient demographic and baseline characteristics in pharmacogenomics analysis.
Characteristic | MOBILITY (n = 642) | TARGET (n = 368) | ASCERTAIN (n = 65) | Total (n = 1075) |
|---|---|---|---|---|
Genetically determined ancestry, n (%) | ||||
European | 362 (56) | 189 (51) | 46 (71) | 597 (55) |
Admixed American | 206 (32) | 158 (43) | 18 (27) | 382 (36) |
African | 23 (4) | 15 (4) | 1 (2) | 39 (4) |
Asian | 32 (5) | 6 (2) | 0 (0) | 38 (4) |
Other | 19 (3) | 0 (0) | 0 (0) | 19 (2) |
Treatment status, n (%) | ||||
Sarilumab + DMARD | 440 (69) | 250 (68) | 65 (100) | 755 (70) |
Placebo + DMARD | 202 (31) | 118 (32) | 0 (0) | 320 (30) |
Age, mean years ± SD | 51.13 ± 12.32 | 53.07 ± 12.4 | 52.8 ± 12.41 | 52.8 ± 12.41 |
Gender, n (%) | ||||
Male | 134 (21) | 62 (17) | 14 (22) | 210 (20) |
Female | 508 (79) | 306 (83) | 51 (78) | 865 (80) |
Baseline biomarkers, mean ± SD | ||||
Total bilirubin, mg/dl | 0.39 ± 0.18 | 0.38 ± 0.17 | 0.45 ± 0.20 | 0.39 ± 0.18 |
Conjugated bilirubin, mg/dl | 0.10 ± 0.05 | 0.10 ± 0.04 | 0.12 ± 0.06 | 0.10 ± 0.05 |
Unconjugated bilirubin, mg/dl | 0.26 ± 0.16 | 0.25 ± 0.15 | 0.31 ± 0.17 | 0.26 ± 0.16 |
Alanine transaminase, ukat/l | 0.36 ± 0.24 | 0.36 ± 0.22 | 0.36 ± 0.19 | 0.36 ± 0.22 |
Aspartate transaminase, ukat/l | 0.36 ± 0.17 | 0.35 ± 0.16 | 0.39 ± 0.13 | 0.36 ± 0.16 |
